Self-Emulsifying Drug Delivery for NRC-AN-019 Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in developing an oral dosage form for NRC-AN-019, a poorly soluble phenylaminopyrimidine derivative, to enhance bioavailability and therapeutic efficacy for treating Chronic Myeloid Leukemia and other cancers, as conventional formulations exhibit low bioavailability and variable therapeutic levels due to insolubility in aqueous media.
Innovation Solution
A self-emulsifying drug delivery formulation comprising NRC-AN-019, a lipophilic phase, surfactants, and a water-miscible solvent, which forms an in-situ emulsion upon gastric fluid contact, improving absorption and bioavailability by solubilization, reducing p-glycoprotein mediated efflux, and enhancing lymphatic transport.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional tablet or capsule formulations are used for NRC-AN-019, then the dosage form is simple and easy to manufacture, but the bioavailability is low due to poor solubility in aqueous media
Solution Approach 1:
The patent changes the physical and chemical parameters of the formulation by using a self-emulsifying drug delivery system (SEDDS) with specific lipid phases, surfactants, and co-surfactants. This transforms the drug from an insoluble crystalline form into a liquid solution that forms fine emulsion droplets upon contact with gastric fluids, dramatically improving solubility and bioavailability without requiring complex manufacturing processes
Solution Approach 2:
The formulation employs a composite system combining multiple components: lipid phases (triglycerides, diglycerides, monoglycerides, fatty acids), surfactants (Tween 80, Span 80, lecithin), and co-surfactants (polyethylene glycols, propylene glycol). This composite material approach creates a synergistic effect where each component contributes to the overall emulsification and solubilization properties, achieving high bioavailability while maintaining formulation simplicity
2Reliability
If the drug is formulated to improve solubility, then bioavailability increases, but the formulation complexity and number of components increase
Solution Approach 1:
The patent optimizes the concentration ratios and physical states of formulation components to achieve rapid self-emulsification. By adjusting parameters such as the HLB value of surfactant combinations, the chain length of fatty acids, and the molecular weight of polyethylene glycols, the formulation achieves enhanced absorption rate through controlled emulsion droplet formation without requiring an excessive number of components
Solution Approach 2:
The patent uses surfactants and co-surfactants as intermediary substances that facilitate the interaction between the lipophilic drug and aqueous gastric fluids. These intermediaries reduce surface tension and promote spontaneous emulsification, enabling improved absorption with a manageable number of formulation components rather than requiring complex multi-component systems
3Reliability
If lipid-based formulation is used to enhance bioavailability, then therapeutic efficacy improves, but the stability during storage may be compromised
Solution Approach 1:
The patent carefully selects and optimizes the chemical parameters of lipid phases and surfactants to balance therapeutic efficacy with storage stability. By choosing saturated and unsaturated fatty acids with appropriate chain lengths, and selecting surfactants with suitable HLB values, the formulation maintains both high bioavailability and stability throughout the storage period, preventing oxidation, hydrolysis, and phase separation
Solution Approach 2:
The patent addresses potential stability issues by incorporating antioxidant agents and chelating agents into the formulation. These additives convert potential harmful effects (oxidation of lipids, metal-catalyzed degradation) into beneficial outcomes by preventing degradation products, thereby maintaining both therapeutic efficacy and storage stability of the lipid-based system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves higher bioavailability and more consistent therapeutic levels, with improved absorption rates and stability, as evidenced by increased AUC and Cmax values compared to traditional capsule forms, while maintaining stability throughout the storage period.
Implementation Method 1
The formulation of the present invention is intended for self-emulsification in-vivo when it comes into contact with the gastric fluids
Implementation Method 2
improving absorption and bioavailability by solubilization
Implementation Method 3
A self-emulsifying drug delivery formulation comprising NRC-AN-019, a lipophilic phase, surfactants, and a water-miscible solvent
Implementation Method 4
enhancing lymphatic transport
Data Source
Figure 1
AI summary
An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal fluid. The invention also relates to a process for the preparation of oral solution containing NRC-AN-019 in an effective concentration for the better therapy against Chronic Myeloid Leukemia as BCR-ABL tyrosine kinase inhibitor and against other tumors such as head and neck cancer, prostate cancer and the like.